Original from: Caris Life Sciences Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced the U.S. Food and Drug Administration (FDA..

Original from: Lucid Diagnostics Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:..

Mainz Biomed N.V. (NASDAQ:MYNZ) (¡°Mainz Biomed¡± or the ¡°Company¡±), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (¡°Thermo Fisher¡±), a world leader in supplying life sciences solutions and services.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024.

Innovative Products The following innovative products have obtained the registration certificate of regulatory authorities for the first time in the industry based on the technology platform, and are open to the..

Original from: Diasorin ¡¤ Revenues: € 876 million, +4% ¡°as reported¡± compared to September 2023; +7% ex covid (+8% at constant perimeter of Consolidation1) ¡¤ Adjusted2 ebitda3: € 2..

Siemens Healthineers AG today announces its results for the fourth quarter of fiscal year 2024 ended September 30, 2024, and the full fiscal year 2024.

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024.

On November 8, 2024, Roche Diagnostics enhanced the company's long term commitment to China's local healthcare industry, to ultimately benefit patients in China and beyond, with the opening of its new Roche Diagnostics Head Office in China.

Original from: BD BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2024 fourth quarter and full year which ended Septemb..

Original from: QuidelOrtho Third Quarter 2024 Results and Recent Developments (all comparisons are to the prior year period) ¡¤ Reported revenue was $727 million - Recurring revenue1 w..

As of 31 October, 2024, all mainland-listed Chinese IVD companies have released their third-quarter financial reports. This summary provides insights into 50 main IVD enterprises and 20 IVD-related enterprises for ref..

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024.

Orginal from: Qiagen ¡¤ Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 ¡¤ Net sales of $502 millio..

CareDx, Inc. (Nasdaq: CDNA) ¨C today announced financial results for the third quarter ended September 30, 2024.